Credit Suisse’s Sarepta Therapeutics SRPT Stock Holding History

Credit Suisse’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20,600	Closed	-$1.85M	–	4262
2021 Q4	$1.85M	Buy	20,600 +1,700	+9%	+$145K	﹤0.01%	2849
2021 Q3	$1.75M	Sell	18,900 -8,900	-32%	-$686K	﹤0.01%	2916
2021 Q2	$2.16M	Sell	27,800 -8,400	-23%	-$637K	﹤0.01%	2805
2021 Q1	$2.7M	Buy	+36,200	New	+$3.34M	﹤0.01%	2589
2015 Q1	–	Sell	-200,000	Closed	-$2.89M	–	4565
2014 Q4	$2.89M	Hold	200,000	–	–	﹤0.01%	2221
2014 Q3	$4.22M	Buy	+200,000	New	+$4.51M	﹤0.01%	1885

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Credit Suisse's SRPT Position: Q1 2024 in Review

Credit Suisse increased its Sarepta Therapeutics (SRPT) stake by 5% in Q1 2024, buying an estimated $1.03M and bringing the position to 176,136 shares worth $22.8M. The position accounts for 0.02% of the portfolio, ranked #600.

Credit Suisse first reported a position in SRPT in Q2 2013 and has held it in 44 quarters since. The position peaked at $80.8M in Q4 2020. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

Credit Suisse held 176,136 shares of Sarepta Therapeutics worth $22.8M as of Q1 2024.
Credit Suisse bought 8,399 Sarepta Therapeutics shares in Q1 2024, an estimated $1.03M.
Sarepta Therapeutics made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #600 holding.
Credit Suisse first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's Sarepta Therapeutics position peaked at $80.8M in Q4 2020.
414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.